Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana 133207, India.
Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, USA.
Toxicol In Vitro. 2021 Jun;73:105142. doi: 10.1016/j.tiv.2021.105142. Epub 2021 Mar 17.
Oncogenic transformation has been the major cause of global mortality since decades. Despite established therapeutic regimes, majority of cancer patients either present with tumor relapse, refractory disease or therapeutic resistance. Numerous drug candidates are being explored to tap the key reason being poor tumor remission rates, from novel chemotherapy agents to immunotherapy to exploring natural compound derivatives with effective anti-cancer potential. One of these natural product metabolites, emodin has present with significant potential to target tumor oncogenic processes: induction of apoptosis and cell cycle arrest, tumor angiogenesis, and metastasis to chemoresistance in malignant cells. Based on the present scientific excerpts on safety and effectiveness of emodin in targeting hallmarks of tumor progression, emodin is being promisingly explored using nanotechnology platforms for long-term sustained treatment and management of cancer patients. In this review, we summarize the up-to-date scientific literature supporting the anti-neoplastic potential of emodin. We also provide an insight into toxicity and safety profile of emodin and how emodin has emerged as an effective therapeutic alternative in synergism with established conventional chemotherapeutic regimes for management and treatment of tumor progression.
几十年来，致癌转化一直是全球死亡的主要原因。尽管有既定的治疗方案，但大多数癌症患者要么出现肿瘤复发、难治性疾病或治疗耐药性。正在探索大量的候选药物，主要原因是肿瘤缓解率低，从新型化疗药物到免疫疗法，再到探索具有有效抗癌潜力的天然化合物衍生物。这些天然产物代谢物之一，大黄素具有显著的靶向肿瘤致癌过程的潜力：诱导细胞凋亡和细胞周期停滞、肿瘤血管生成以及转移到恶性细胞的化疗耐药性。基于大黄素在靶向肿瘤进展标志方面的安全性和有效性的现有科学摘录，大黄素正在使用纳米技术平台进行探索，以实现癌症患者的长期持续治疗和管理。在这篇综述中，我们总结了支持大黄素抗肿瘤潜力的最新科学文献。我们还深入了解了大黄素的毒性和安全性概况，以及大黄素如何与既定的常规化疗方案协同作用，成为管理和治疗肿瘤进展的有效治疗替代方案。
